REG - LungLife AI, INC - Change of Nominated Adviser and Joint Broker

LungLife AIAnnouncement

10/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250210:nRSJ4275Wa&default-theme=true

RNS Number : 4275W  LungLife AI, INC  10 February 2025

10 February 2025

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Change of Nominated Adviser and Joint Broker

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces the appointment of Allenby Capital Limited as the Company's
Nominated Adviser and Joint Broker with immediate effect, alongside the
Company's existing Joint broker, Goodbody.

 

AIM Rule 17 Schedule Two (g) information:

 

The Company also provides the following information relating to directors'
disclosure under Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for
Companies:

 

LungLife's Chairman, Gordon Davis, was a director of C-Quential Limited until
his resignation on 28 February 2001.  C-Quential Limited entered into a
creditors voluntary liquidation on 11 February 2002 and was subsequently
dissolved on 18 August 2007.

 

 

For further information please contact:

 

 LungLife AI, Inc.                                                    www.lunglifeai.com (http://www.lunglifeai.com)

 Paul Pagano, CEO                                                     via investors@lunglifeai.com (mailto:investors@lunglifeai.com)

 David Anderson, CFO

 Allenby Capital Limited                                              Tel: +44 (0)20 3328 5656

 Nominated Adviser and Joint Broker                                   info@allenbycapital.com (mailto:info@allenbycapital.com)

 Alex Brearley / Lauren Wright - Corporate Finance

 Matt Butlin / Guy McDougall - Equity Sales & Corporate Broking

 Goodbody                                                             Tel: +44 (0) 20 3841 6202

 Joint Broker

 Tom Nicholson / Cameron Duncan

 

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com/)

 

Our Purpose is to be a driving force in the early detection to lung
cancer. And our Vision is to invert the 20:80 ratio such that in years to
come at least 80% of lung cancer is detected early.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPTLMJTMTMMBIA